Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease Darbie Maccubbin, PhD, Michael J. Koren, MD, Michael Davidson, MD, Dov Gavish, MD, Richard C. Pasternak, MD, Geraldine Macdonell, MHA, Madhuja Mallick, PhD, Christine McCrary Sisk, BS, John F. Paolini, MD, PhD, Yale Mitchel, MD American Journal of Cardiology Volume 104, Issue 1, Pages 74-81 (July 2009) DOI: 10.1016/j.amjcard.2009.02.047 Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 1 Study design. e-diaries = electronic diaries; PBO = placebo; R = randomization. American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 2 Number of days per week with moderate, severe or extreme flushing (GFSS ≥4) across the treatment period, categorized as 0 day (black bars), >0 and ≤0.5 day (dotted bars), >0.5 and ≤1 day (striped bars), >1 and ≤2 days (dark gray bars), >2 and ≤3 days (white bars), and >3 days (light gray bars) per week. American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 3 (A) Mean ± SE number of days per week and (B) percentage of patients with moderate, severe, or extreme flushing (GFSS ≥4) by week. American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 4 Cumulative discontinuations due to (A) flushing and (B) flushing plotted against cumulative dose of niacin. American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 5 Changes over time in (A) low-density lipoprotein cholesterol (LDL-C), (B) high-density lipoprotein cholesterol (HDL-C), and (C) triglyceride. *Percent change from baseline (average of weeks 8 through 16). American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions
Figure 6 Cumulative discontinuations due to (A) nonflushing clinical and laboratory AEs and (B) nonflushing clinical and laboratory AEs plotted against cumulative dose of niacin. American Journal of Cardiology 2009 104, 74-81DOI: (10.1016/j.amjcard.2009.02.047) Copyright © 2009 Elsevier Inc. Terms and Conditions